Something old, something new and something very old: drugs for treating type 2 diabetes - sprookjes - yvandenbroek - TriplyDB

Something old, something new and something very old: drugs for treating type 2 diabetes

Something old, something new and something very old: drugs for treating type 2 diabetes

http://www.wikidata.org/entity/Q26865663

about

Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress.Salidroside improves glucose homeostasis in obese mice by repressing inflammation in white adipose tissues and improving leptin sensitivity in hypothalamus.An adenovirus-derived protein: A novel candidate for anti-diabetic drug development.Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Synthesis of furostanol glycosides: discovery of a potent α-glucosidase inhibitor.

P2860

Q33812543-5BE4748E-E7A2-4412-874D-2E3B76E71D2F Q36870929-7265D60B-AFC6-41B0-A28F-291601CE9156 Q37446084-61485B1A-B4FB-4CC1-BD51-4F1E57D5046F Q38398128-4AC5F4BD-BB10-4BDA-94FE-9CCB1599D24B Q54515075-B237363C-93C0-4545-9568-1579C1CD1597

P2860

Something old, something new and something very old: drugs for treating type 2 diabetes

http://www.wikidata.org/entity/Q26865663

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Something old, something new and something very old: drugs for treating type 2 diabetes

@ast

Something old, something new and something very old: drugs for treating type 2 diabetes

@en

Something old, something new and something very old: drugs for treating type 2 diabetes

@nl

type

label

Something old, something new and something very old: drugs for treating type 2 diabetes

@ast

Something old, something new and something very old: drugs for treating type 2 diabetes

@en

Something old, something new and something very old: drugs for treating type 2 diabetes

@nl

prefLabel

Something old, something new and something very old: drugs for treating type 2 diabetes

@ast

Something old, something new and something very old: drugs for treating type 2 diabetes

@en

Something old, something new and something very old: drugs for treating type 2 diabetes

@nl

P1433

Q26865663-6484ED3A-D0A9-450F-98EF-F8EC43A231A1

P1476

Q26865663-B5ECAD82-D38E-4158-A0ED-196D43CA5A87

P2093

Q26865663-4D01B75D-C831-493C-9AC7-C37EB6D4301A

Q26865663-B53A42CC-00D1-4398-B027-4E58C7772C20

P2860

Q26865663-00AC3E99-1E58-41EB-A4BF-A34B47B6008D

Q26865663-02DFCE71-AF06-41BA-B4C2-64DFD99B0B7D

Q26865663-0579EA95-3825-43E5-8E1B-4D50429E5716

Q26865663-059B0EDE-F34E-4A00-9F81-B4E4F0CFCDFE

Q26865663-0B681B79-291E-48D1-AC7E-F895A1BECA45

Q26865663-0BCA28BD-389C-4742-A40C-6D4A54C24450

Q26865663-0E216135-AE73-4871-8E5F-6161E0EADB29

Q26865663-1086E4A3-2CFD-42A5-8372-C041133030A1

Q26865663-137116D8-4229-481E-A3F5-7A24A00DB9F8

Q26865663-145D0635-66C0-480D-983E-C3FC1B4ACD44

P304

Q26865663-4E9794C5-9137-434B-80FF-FFAE22E50F05

P31

Q26865663-080D8CF1-A531-45C8-8F6A-FEB9C433795C

P3181

Q26865663-D723424E-46C0-416D-99E5-2D944A68E145

P356

Q26865663-2D55121E-E93E-4FC9-A96E-3AE7A26C20BE

P407

Q26865663-0E545A71-A46F-48EE-A0EA-EFC39FB1535D

P433

Q26865663-B59F54E8-083A-4758-B7F5-1EE4F19C159A

P478

Q26865663-FC68129C-2C44-46A8-8ECF-CD6586AE2A13

P577

Q26865663-CDAF9540-FE48-49D1-B91B-A7E1195D2810

P5875

Q26865663-B0215FB6-5A90-4231-89E4-8BB62E6352FA

P698

Q26865663-5D1617B4-2546-4C39-A643-6DA38CBD16A2

P921

Q26865663-4599A8B5-52A3-482A-91DE-EC9623E19EED

P932

Q26865663-3DC1EC2B-828E-4125-842E-3908F88CA38B

P3181

P356

P1433

British Journal of Pharmacology

P1476

Something old, something new and something very old: drugs for treating type 2 diabetes

@en

P2093

D Kaiser

http://www.w3.org/2001/XMLSchema#string

E Oetjen

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical Pharmacokinetics of Metformin

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

Molecular mechanism of action of metformin: old or new insights?

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

The ancient drug salicylate directly activates AMP-activated protein kinase

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

P304

2940-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1844368

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/BPH.12624

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

171

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260914301

http://www.w3.org/2001/XMLSchema#string

P698

24641580

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4055198

http://www.w3.org/2001/XMLSchema#string